Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation for Apellis Pharmaceuticals’ (NASDAQ: APLS) New Drug Application (NDA) for the intravitreal pegcetacoplan.
The regulatory agency has assigned target action date of November 26, 2022.
